Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
First Year
100%
Myopic Choroidal Neovascularization (mCNV)
100%
Subgroup Analysis
100%
Ranibizumab
100%
Neovascular Age-related Macular Degeneration (nAMD)
100%
Photodynamic Therapy
80%
Baseline Visual Acuity
80%
Acuity Score
80%
Visual Acuity
60%
Lesion Size
60%
Visual Acuity Outcome
60%
Multivariate Analysis
40%
Phase II Study
40%
Change from Baseline
40%
Age-related Macular Degeneration
20%
Patient Characteristics
20%
Treatment Outcome
20%
Disease Pattern
20%
Univariate Analysis
20%
Lesion Types
20%
Patient Gender
20%
Verteporfin
20%
Ranibizumab Treatment
20%
Change Score
20%
Marina
20%
Small Baseline
20%
Lesion Age
20%
Medicine and Dentistry
Visual Acuity
100%
Subgroup Analysis
100%
Ranibizumab
100%
Wet Macular Degeneration
100%
Choroidal Neovascularization
50%
Photochemotherapy
40%
Multivariate Analysis
20%
Diseases
10%
Age Related Macular Degeneration
10%
Univariate Analysis
10%
Verteporfin
10%
Treatment Outcome
10%
Pharmacology, Toxicology and Pharmaceutical Science
Ranibizumab
100%
Wet Macular Degeneration
100%
Subretinal Neovascularization
83%
Photodynamic Therapy
66%
Diseases
16%
Age Related Macular Degeneration
16%
Verteporfin
16%
Neuroscience
Age-Related Macular Degeneration
100%
Ranibizumab
100%
Visual Acuity
100%
Choroidal Neovascularization
50%
Verteporfin
10%
Psychology
Visual Acuity
100%
Multivariate Analysis
20%
Univariate Statistics
10%